Fractyl Health, Inc. Common Stock (GUTS)
Automate Your Wheel Strategy on GUTS
With Tiblio's Option Bot, you can configure your own wheel strategy including GUTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GUTS
- Rev/Share 0.0003
- Book/Share -0.3713
- PB -2.7613
- Debt/Equity -3.3889
- CurrentRatio 1.2224
- ROIC -2.2087
- MktCap 74027492.0
- FreeCF/Share -1.679
- PFCF -0.899
- PE -0.5041
- Debt/Assets 0.9954
- DivYield 0
- ROE -5.9643
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Fractyl Health: Speculative Buy With Binary Risk
Published: July 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected in Q3 2025. Current valuation reflects financing and trial risks, but may underappreciate Revita's clinical potential as a durable alternative to GLP-1 drugs. The company's cash runway is critically short, making the REMAIN-1 midpoint data a financial survival catalyst for raising capital on favorable terms.
Read More
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure
Read More
Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity
Read More
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1 TM gene therapy for patients with inadequately controlled T2D and obesity
Read More
Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases
Published: May 14, 2025 by: Business Wire
Sentiment: Neutral
COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV development and manufacturing agreement to help advance Fractyl Health's Rejuva* pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes (T2D). "We developed our FUEL™ platform to provide developers like Fractyl with a more efficient and scalable manufacturing solution to help.
Read More
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m.
Read More
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BURLINGTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering pattern breaking approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the fourth quarter and full year 2024 and provide business updates on Monday, March 3, 2025, at 4:30 p.m.
Read More
About Fractyl Health, Inc. Common Stock (GUTS)
- IPO Date 2024-02-02
- Website https://fractyl.com
- Industry Biotechnology
- CEO Harith Rajagopalan
- Employees 107